IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer
IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has announced the appointment of Uri Birenberg as its new Chief Financial Officer (CFO). Birenberg brings over two decades of experience in financial planning and analysis to the company, having previously served as CFO of Hygear Ltd, a startup in the healthcare fitness tech industry.
The addition of Birenberg to IM Cannabis Corp.’s leadership team is expected to strengthen the company’s financial leadership and strategic direction, supporting its goal of achieving sustainable profitability. Oren Shuster, CEO of IMC, expressed his delight at welcoming Birenberg to the team, highlighting his impressive track record and extensive experience with large-scale international organizations and startups.
In his new role, Birenberg will play a critical part in helping IM Cannabis Corp. achieve its financial and strategic objectives, as well as further strengthening the partnership with investors. With a focus on sustainable growth and a passion for innovative solutions, Birenberg is expected to make significant contributions to the company’s continued success.
Birenberg himself expressed his excitement about joining IM Cannabis Corp. at this crucial stage of its development. He looks forward to working with CEO Oren Shuster and the team to deliver on the company’s strategic priority of achieving sustainable profitability.
The transition process will be smooth, as Birenberg will work closely with the outgoing CFO, Itay Vago, until Vago presents the Q3 2023 results in November. This ensures a seamless handover of responsibilities and knowledge transfer.
IM Cannabis Corp. is an international cannabis company that focuses on providing premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company recently made the strategic decision to exit operations in Canada and redirect its focus and resources towards achieving sustainable and profitable growth in its highest value markets.
The company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients. IM Cannabis Corp. also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel, ensuring the safe delivery and quality control of its products throughout the entire value chain.
In Germany, IM Cannabis Corp. operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The company’s transnational ecosystem leverages a unique data-driven approach and a globally sourced product supply chain. IM Cannabis Corp. is committed to responsible growth and compliance with the strictest regulatory environments, aiming to become a global high-quality cannabis player.
With the appointment of Uri Birenberg as CFO, IM Cannabis Corp. is well-positioned to continue its growth trajectory and achieve its financial and strategic goals. The company’s focus on Israel and Germany, coupled with its commitment to delivering premium cannabis products, sets the stage for a promising future in the medical cannabis industry.